Phase 1 Brain Cancer Trial, Recruiting NCT04185038 Sponsor: Seattle Children's Hospital Condition: Brain Cancer
Back to Brain Cancer

Phase 1 Brain Cancer Trial, Recruiting

NCT04185038
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 1 and 26 years old
  • You have a brain or spinal cord tumor that has come back or stopped responding to treatment and there are no standard treatment options left, OR you have a specific type of brainstem tumor (DIPG or DMG) and have already finished standard treatment
  • You are able to undergo a procedure to collect immune cells from your blood (called apheresis), or your immune cells have already been collected and are available to use
  • You have a small device (such as an Ommaya or Rickham reservoir) already placed in your brain or spinal area to deliver treatment
  • Doctors expect you to live for at least 8 weeks
  • You are still able to carry out a reasonable amount of daily activities, as measured by a standard medical scoring tool
  • If your immune cells have not already been collected, enough time has passed since your last cancer treatments (chemotherapy, radiation, immunotherapy, or antibody therapy) and your body has recovered from their side effects
  • If you are taking steroid medications (like dexamethasone), your dose has been stable or reducing in the week before joining, and is below a certain level
  • Your heart, liver, kidneys, and other organs are working well enough
  • Your blood test results meet the required levels
  • If you are able to have children, you agree to use highly effective birth control during the trial

Who may not be able to join:

  • You have significant heart problems or a serious irregular heartbeat that needs medical treatment
  • You have a condition where your immune system does not work properly, or your bone marrow does not produce enough blood cells
  • There are signs — from symptoms or scans — that your brain may be at risk of a dangerous shift or herniation
  • You have severe difficulty swallowing (beyond a certain level of severity)
  • You have another active cancer in addition to your brain or spinal cord tumor
  • You currently have a serious active infection
  • You are currently receiving any anti-cancer treatment or chemotherapy
  • You are pregnant or breastfeeding
  • You or your legal guardian are unwilling or unable to agree to being followed up for 15 years after the trial
  • You have any other condition that the trial doctor believes would make it unsafe for you to take part (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Rebecca Ronsley, MD, Seattle Children's Hospital

Phone: 206-987-2106

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Seattle Children's Hospital
Registry
ClinicalTrials.gov
Start date
11 December 2019
Est. completion
1 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Establish the safety, defined by the adverse events, of B7H3-specific CAR T cell infusions delivered by a central nervous system (CNS) catheter into the tumor resection cavity or ventricular system; Establish the feasibility, defined by the ability to produce and administer CAR T cell product, of B7H3-specific CAR T cell product infusions delivered by a central nervous system (CNS) catheter into the tumor resection cavity or ventricular system

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov